Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations

Monica Sharma,Seema Tyagi,Preeti Tripathi,Tulika Seth 대한혈액학회 2018 Blood Research Vol.53 No.3

Background Syndecan-1 (sCD138) has recently been suggested to predict the clinical course of ear-ly-stage chronic lymphocytic leukemia (CLL), but few studies have been reported. This study assessed the role of syndecan-1 in the prognosis of patients with CLL and its correla-tion with other prognostic markers. Methods This prospective study was performed in the hematology department of an Indian tertiary care center, over nineteen months (Jun. 2009‒Jan. 2011). Forty-nine new patients with CLL presented during this period and were included. Twenty age- and gender-matched healthy patients served as controls, and six patients with multiple myeloma were included as positive controls. Baseline serum syndecan-1 concentrations were measured for all patients at presentation using ELISA (Diaclone, Besancon, France). At baseline, patients were divided into low (N=10), intermediate (N=18) and high (N=21) risk cohorts. Serum syndecan-1 levels in these patient subgroups were compared with clinical and laboratory parameters. Results The median syndecan-1 level in patients with CLL (73.32 ng/mL, range, 28.71‒268.0 ng/mL) was marginally higher than that in healthy patients (63.10 ng/mL, range, 55.0‒75.11 ng/mL). At presentation, syndecan-1 levels in patients with CLL correlated strongly with symptomatic disease (cytopenias, P=0.004) and higher clinical stage (Rai stage III and IV, P=0.001) markers and poorly with 2-microglobulin level (P=0.270), diffuse BM infiltration (P=0.882), and surrogate mutation status markers (CD 38, P=0.174 and ZAP-70, P=0.459). Syndecan-1 levels dichotomized by the median value were higher with progressive disease markers, e.g. shorter lymphocyte doubling time (LDT, P=0.015) and increased treatment (P=0.099). ConclusionIn CLL, serum syndecan-1 (sCD138) levels at presentation correlate with disease burden, and higher baseline levels may predict early treatment.

Synthesis, characterization and adsorptive application of ferrocene based mesoporous material for hazardous dye Congo red

Sumanjit Kaur,Seema Rani,Vipin Kumar,R.K. Mahajan,Mohammad Asif,Inderjeet Tyagi,Vinod Kumar Gupta 한국공업화학회 2015 Journal of Industrial and Engineering Chemistry Vol.26 No.-

Mesoporous adsorbent is prepared first time using ferrocene based surfactant as a template and adsorption of azo dye Congo red is investigated. Adsorbent is characterized by Fourier transform infrared spectroscopy, X-ray diffraction, scanning electron microscopy, transmission electron microscopy, dynamic light scattering and N2 adsorption–desorption and deduced a lofty surface area of 342 m2/g. Effect of contact time, adsorbent dose, initial dye concentration and temperature were speculated to optimize adsorption conditions. Experimental data were contemplated for various kinetics and thermodynamic models at different temperatures and insinuated that adsorption process is film diffusion controlled and followed second order kinetics. Langmuir model imparted high value of monolayer capacity as 312.5 mg/g. The values of thermodynamic parameters like enthalpy (DH) and entropy (DS) were found to be 49.94 kJ/mol and 265.5 J/K/mol, respectively, and negative values of DG corroborated that the present adsorption system is feasible, spontaneous and endothermic.

Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations

Monica Sharma,Seema Tyagi,Preeti Tripathi,Tulika Seth 대한혈액학회 2018 Blood Research Vol.53 No.3

Background Syndecan-1 (sCD138) has recently been suggested to predict the clinical course of ear-ly-stage chronic lymphocytic leukemia (CLL), but few studies have been reported. This study assessed the role of syndecan-1 in the prognosis of patients with CLL and its correla-tion with other prognostic markers. Methods This prospective study was performed in the hematology department of an Indian tertiary care center, over nineteen months (Jun. 2009‒Jan. 2011). Forty-nine new patients with CLL presented during this period and were included. Twenty age- and gender-matched healthy patients served as controls, and six patients with multiple myeloma were included as positive controls. Baseline serum syndecan-1 concentrations were measured for all patients at presentation using ELISA (Diaclone, Besancon, France). At baseline, patients were divided into low (N=10), intermediate (N=18) and high (N=21) risk cohorts. Serum syndecan-1 levels in these patient subgroups were compared with clinical and laboratory parameters. Results The median syndecan-1 level in patients with CLL (73.32 ng/mL, range, 28.71‒268.0 ng/mL) was marginally higher than that in healthy patients (63.10 ng/mL, range, 55.0‒75.11 ng/mL). At presentation, syndecan-1 levels in patients with CLL correlated strongly with symptomatic disease (cytopenias, P=0.004) and higher clinical stage (Rai stage III and IV, P=0.001) markers and poorly with 2-microglobulin level (P=0.270), diffuse BM infiltration (P=0.882), and surrogate mutation status markers (CD 38, P=0.174 and ZAP-70, P=0.459). Syndecan-1 levels dichotomized by the median value were higher with progressive disease markers, e.g. shorter lymphocyte doubling time (LDT, P=0.015) and increased treatment (P=0.099). ConclusionIn CLL, serum syndecan-1 (sCD138) levels at presentation correlate with disease burden, and higher baseline levels may predict early treatment.

Melanization plasticity of Drosophila kikkawai, Drosophila leontia and reciprocal hybrids under different temperatures

Singh Divya,Ramniwas Seema,Tyagi Pankaj Kumar,Kumar Girish,Gola Deepak 한국응용곤충학회 2022 Journal of Asia-Pacific Entomology Vol.25 No.1

Drosophila (Sophophora) kikkawai, Burla, 1954 and Drosophila (Sophophora) leontia, Tsacas & David 1978 are closely related sibling species, the former being cosmopolitan and the latter is restricted to tropical localities. We investigated the influence of introgressive hybridization on phenotypic diversity of the two sibling species in the present study. How hybridization supports the relative abundance of pure species according to latitudinal cline is the aim of this study because hybrids show a tendency to acquire geographical location of their parent species in equal or greater abundance. How hybridization supports the plasticity for melanization of hybrids is not explored yet. The two species can cross and generate hybrids. For this, we crossed true breeding strains of both species to obtain the hybrids i.e. dark female (♀) of D. kikkawai (D. k) with males (♂) of D. leontia (D. l) in cross I and light ♀ of D. k with ♂ of D. l in cross II along with their reciprocal crosses. Finally, we studied the plasticity of both species and their hybrids at 6 growth temperatures (14, 17, 21, 25, 28 and 31 ◦ C). We found that there is no plasticity for melanization in true breeding darker and lighter strain of D. kikkawai as well as D. leontia whereas hybrids of both species showed high phenotypic plasticity. Significant differences in slope values across tem peratures in parental and hybrid lines suggest plastic effects. Phenotypic variation in abdominal melanization in hybrids can be interpreted as a result of gene introgression with D. kikkawai. We conclude that introgressive hybridization might be an important, although underestimated, mechanism shaping species distribution and adaptation.

Cytoplasmic azurophilic inclusion bodies in reactive plasmacytosis

Aastha Gupta,Preeti Tripathi,Seema Tyagi 대한혈액학회 2018 Blood Research Vol.53 No.4

Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective

Rahul Kumar Sharma,Abhishek Purohit,Venkatesan Somasundaram,Pravas Chandra Mishra,Mrinalini Kotru,Ravi Ranjan,Sunil Kumar,Sudha Sazawal,Hara Prasad Pati,Seema Tyagi,Renu Saxena 대한혈액학회 2014 Blood Research Vol.49 No.4

Background Aberrant myeloid antigen (MA) co-expression and high expression of CD34 antigen on the blasts of acute lymphoblastic leukemia (ALL) patients are independently reported to have a role in pathogenesis and prognosis. This study was conducted to determine whether these two parameters are related. Methods A total of 204 cases of ALL were included in an analysis of blast immunophenotypic data. CD34 expression was categorized as low when less than 50% of blasts were CD34-positive (CD34low) and as high when 50% or more were CD34-positive (CD34high). Results Of 204 cases of ALL, 163 and 41 were of B-cell origin (B-ALL) and T-cell origin (T-ALL), respectively. Of all cases, 132 (64.7%) showed co-expression of MA and among these, 101 (76.51%) were CD34high, while the remaining 31 (23.48%) were CD34low. Of 72 cases without MA co-expression, 25 (34.72%) were CD34high and 47 (67.25%) were CD34low. Furthermore, of 163 cases of B-ALL, 111 showed co-expression of MA and 84 of these were CD34high. Of 52 cases of B-ALL without MA expression, 22 were CD34high. Among 41 cases of T-ALL, 21 co-expressed MA, 17 of which were CD34high. Moreover, all 20 cases of T-ALL without co-expression of MA were CD34low. These differences were statistically significant. Conclusion We observed a strong correlation between aberrant MA expression and CD34high expression on the blasts of ALL. We hypothesize that these different patient subsets may represent unique prognostic characteristics.

Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective

Rahul Kumar Sharma,Abhishek Purohit,Venkatesan Somasundaram,Pravas Chandra Mishra,Mrinalini Kotru,Ravi Ranjan,Sunil Kumar,Sudha Sazawal,Hara Prasad Pati,Seema Tyagi,Renu Saxena 대한혈액학회 2014 Blood Research Vol.49 No.4

Background Aberrant myeloid antigen (MA) co-expression and high expression of CD34 antigen on the blasts of acute lymphoblastic leukemia (ALL) patients are independently reported to have a role in pathogenesis and prognosis. This study was conducted to determine whether these two parameters are related. Methods A total of 204 cases of ALL were included in an analysis of blast immunophenotypic data. CD34 expression was categorized as low when less than 50% of blasts were CD34-positive (CD34low) and as high when 50% or more were CD34-positive (CD34high). Results Of 204 cases of ALL, 163 and 41 were of B-cell origin (B-ALL) and T-cell origin (T-ALL), respectively. Of all cases, 132 (64.7%) showed co-expression of MA and among these, 101 (76.51%) were CD34high, while the remaining 31 (23.48%) were CD34low. Of 72 cases without MA co-expression, 25 (34.72%) were CD34high and 47 (67.25%) were CD34low. Furthermore, of 163 cases of B-ALL, 111 showed co-expression of MA and 84 of these were CD34high. Of 52 cases of B-ALL without MA expression, 22 were CD34high. Among 41 cases of T-ALL, 21 co-expressed MA, 17 of which were CD34high. Moreover, all 20 cases of T-ALL without co-expression of MA were CD34low. These differences were statistically significant. Conclusion We observed a strong correlation between aberrant MA expression and CD34high expression on the blasts of ALL. We hypothesize that these different patient subsets may represent unique prognostic characteristics.